Abbisko Therapeutics

Biomarkers

• FGFR3 alteration (mutation or fusion)2
• EGFR exon 19 deletion / L858R1
• EGFR exon 20 insertion1
• KRAS G12C1
• KRAS G12D1
• FGFR2 fusion or rearrangement1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

osimertinib 1glecirasib 1furmonertinib 1ABSK061 1

Trials

8 of 12 trials shown

1. A Phase 2 Study of ABSK043 Combined With Osimertinib

   Not yet recruiting Phase 2 Abbisko Therapeutics Started 2026Primary completion 2029-12 NCT07710612

   osimertinib FDA EU

   Documented genetic testing report confirms the presence of EGFR alteration(s) in tumor or plasma.

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

2. A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

   Recruiting Phase 1/2 Abbisko Therapeutics Started 2026Primary completion 2028-12 NCT07417189

   ABSK141-400mgABSK141-Recommended Dose for Expansion (RDE)ABSK141-800mgABSK141-1200mgABSK141-Recommended Phase 2 dose (RP2D)

   Patients must have the following solid tumor harboring KRAS G12D mutation:

   KRAS G12DSolid Tumors, Adult

3. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

   Recruiting Phase 2 Abbisko Therapeutics Started 2025Primary completion 2028-12 NCT07164170

   glecirasib

   Tumor tissue or blood test report confirmed KRASG12C mutation.

   KRAS G12CNon-Small Cell Lung Cancer

4. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

   Recruiting Phase 2 Abbisko Therapeutics Started 2024Primary completion 2027-12 NCT06668103

   furmonertinib

   Documented genetic testing reports confirmed the presence of EGFR L858R or EGFR exon 19 del mutations in tumor or plasma ctDNA.

   EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer With EGFR Mutation

5. A Phase 2 Clinical Study of ABSK061 and ABSK043

   Recruiting Phase 2 Abbisko Therapeutics Started 2024Primary completion 2029-11 NCT06632262

   ABSK061CAPOX

   …cified a central laboratory or previous test report confirming the presence of a specific FGFR3 mutation or overexpression, FGFR2/3 fusion in tumor tissue or blood based on central laboratory te…

   FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementHER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors

6. A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

   Recruiting Phase 1 Abbisko Therapeutics Started 2026Primary completion 2029-12 NCT07718165

   ABSK211

   …pants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration

   KRAS G12CKRAS G12DSolid Tumor (Phase I)

7. A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

   Active, not recruiting Phase 1 Abbisko Therapeutics Started 2024Primary completion 2027-03 NCT06225804

   ABSK112

   For the expansion part, patients have documented EGFR in-frame exon 20 insertion mutations confirmed by certificated local laboratories

   EGFR exon 20 insertionNon-Small Cell Lung Cancer

8. A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

   Active, not recruiting Phase 1 Abbisko Therapeutics Started 2023Primary completion 2026-03 NCT05627063

   ABSK121-NX

   Urothelial carcinoma (UC): pre-specified FGFR3 mutations (R248C, S249C, G370C, Y373C) or FGFR2/3 fusions (partner gene is previously described or …

   FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementSolid Tumor

No trials match these filters.